Journal: NPJ breast cancer
The NSABP B-51/RTOG 1304 trial shows that breast cancer patients who achieve nodal clearance after neoadjuvant chemotherapy do not benefit from additional regional nodal irradiation.
This finding:
- Challenges previous treatment norms
- Supports de-escalation of therapy
- Prompts further investigation into the underlying immunologic mechanisms and variations across clinical subgroups